Dr. Karlan Describes AMG 386 Side Effects

Beth Y. Karlan MD
Published: Friday, Apr 29, 2011

Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial
Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x